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ABSTRACT
Background: Chronic kidney disease (CKD) is a signiﬁcant risk
factor for cognitive impairment. Previous studies have exam-
ined differences in cognitive impairment between persons with
and without CKD using multiple cognitive outcomes, but few
have done this for an extensive battery of cognitive tests. We
relate early-stage CKD to two indices of impairment for 22
measures of cognitive ability.
Methods: The study was community-based and cross-sectional
with 898 individuals free from dementia and end-stage renal
disease. Estimated glomerular ﬁltration rate (eGFR) was calcu-
lated using the chronic kidney disease epidemiology collabora-
tion equation and classiﬁed as <60 or 60 mL/min/1.73 m2,
based on consensus deﬁnitions of Stage 3 or greater CKD. The
eGFR classiﬁcations were related to modest [1 standard devia-
tion (SD) below the mean] and severe (1.5 SD below the
mean) impairment on each measure using logistic regression
analyses adjusting for potential risk factors.
Results: A total of 146 individuals (16.3%) had eGFR <60 mL/
min/1.73 m2 (mean 51.66 10.1 mL/min/1.73m2). These partic-
ipants had signiﬁcantly greater risk for modestly impaired abil-
ities in the scanning and tracking and visual-spatial organiza-
tion/memory (VSOM) domains after accounting for
comorbidity-related risk factors [odds ratios (ORs) between
1.68 and 2.16], as well as greater risk for severely impaired func-
tioning in the language domain (OR¼ 2.65).
Conclusions: Participants with eGFR <60 mL/min/1.73 m2
were at higher risk for cognitive impairment than those with
eGFR 60 mL/min/1.73 m2 on the majority of cognitive abil-
ities, speciﬁcally those within the VSOM, Language, and scan-
ning and tracking domains. Targeted screening for cognitive
deﬁcits in kidney disease patients early in their disease course
may be warranted.
Keywords: cardiovascular disease, chronic kidney disease,
CKD-EPI, cognitive impairment, cognitive norms
INTRODUCTION
Chronic kidney disease (CKD) has been identified as a signifi-
cant risk factor for lowered cognitive performance [1–3]. These
deficits appear to be more pronounced in patients with end-
stage renal disease (ESRD) [4–7]. This is a salient public health
issue, as patient burden in the treatment of CKD is heavy and
preventing the development of treatment-related cognitive defi-
cit is important.
Many earlier studies of kidney disease and cognition utilized
one or a few measures of different cognitive abilities. However,
it has since been recognized that individuals with kidney disease
have intact function for some cognitive abilities and significant
impairment in others [1–3]. Abilities at particularly high risk
for impairment are generally thought to be those that rely on
higher-order cognitive domains, including executive function-
ing and abstract reasoning [2, 6]. To date, few studies have uti-
lized multiple cognitive outcome measures in state-of-the-art
neurocognitive test batteries to gain a clearer picture of affected
abilities and the domains that they comprise.
Schneider et al. [4] recently provided clinically relevant data
with regard to performance on tests of multiple cognitive abil-
ities in ESRD utilizing a healthy control group. Though valuable
information was provided in this study, there has been some
debate regarding the suitability of a healthy control group in
studies of cognition and CKD. We have previously suggested
that it may lead to biased comparisons, as differences in com-
mon CKD-related comorbidities (e.g. hypertension, cardiac dis-
eases) may themselves account for lower cognitive performance
[8]. Persons with early-stage CKD would make a better refer-
ence group in future examinations of ESRD, as they have kidney
disease of a less serious nature but potentially similar
comorbidities.
To further evaluate the validity of this recommendation, it
would be important to know the level of modest and more
severe cognitive impairment in persons with early-stage CKD
and to have these data for as many individual measures of||
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|cognitive ability as possible. One shortcoming of previous stud-
ies of early-stage CKD from a clinical perspective is that infor-
mation is not given with respect to individual test scores, e.g.
Elias et al. [9]; rather, scores from individual tests are combined
to make domain (composite) scores. While this approach is
ideal from a theoretical standpoint of cognitive deficit, having
raw scores from individual tests available would also provide
nephrologists with reference data to which they could compare
the performance of their own patients.
In the present study, we report findings for 22 well-
established tests of cognitive ability using data from the
community-based Maine Syracuse Longitudinal Study (MSLS)
[10]. For each of these 22 measures, we express results in terms
of (i) risk for modest cognitive impairment, defined by
Schneider et al. [4] as performance 1.0 standard deviation (SD)
below the mean and (ii) risk for severe cognitive impairment, a
more stringent criterion, defined as performance 1.5 SD below
the mean in the literature [10]. We hypothesize that individuals
with CKD will show deficit in cognitive performance that meets
criteria for modest and severe impairment (compared with a
non-CKD reference group), and that the number of tests for
which impairment is seen will be attenuated with adjustment
for demographic variables, risk factors and CKD-related comor-
bidities [1–4].
MATERIALS AND METHODS
Study design
Data for the present cross-sectional study were obtained
from the sixth wave of the MSLS, a community-based study of
cardiovascular risk factors (CVD-RF) and cognitive function
[11, 12]. Participants were recruited from the Central New York
State area. There were no requirements for participation at base-
line other than the absence of diagnosed psychiatric disorder,
non-institutionalization and absence of alcoholism. Between
2001 and 2006 (wave six), data necessary to examine a broad
range of cognitive measures and to estimate glomerular filtra-
tion rate (eGFR) were obtained for the first time.
Beginning with 1040 study participants, individuals were
excluded based on (i) missing data necessary to calculate eGFR
(n ¼ 77); (ii) dementia (n ¼ 9); (iii) active dialysis treatment (n
¼ 4); (iv) under 40 years of age (n ¼ 29) and (v) missing cogni-
tive data (n¼ 23). The final sample consisted of 898 participants,
752 with eGFR 60 mL/min/1.73 m2 (non-CKD reference
group) and 146 with eGFR<60mL/min/1.73 m2 (CKD group).
The exclusion of dementia cases was based on our interest in
characterizing relationships between CKD and cognition in per-
sons who vary in cognitive function but do not suffer from
major impairment. Clinical diagnoses of dementia were deter-
mined from cognitive data and medical records using the
National Institute of Neurological and Communicative Diseases
and Stroke/Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria [13] and confirmed
using the ICD-10 guidelines [14]. Detailed steps of our diagnos-
tic process can be found in Supplementary data, Appendix 1.
The age exclusion was employed due to a significant imbalance
in age between the two renal function groups when persons
<40 years of age were included.
Procedures
One week prior to neuropsychological testing, participants
in the present study completed the Center for Epidemiological
Studies Depression Scale (CES-D) [15]. A blood sample was
drawn the morning after a fast from midnight. This was fol-
lowed by a light breakfast, medical history, multiple automated
blood pressure (BP) measurements (GE Dinamap 100DPC-
120XEN) and neuropsychological assessment. All assay meth-
ods have been described previously [9, 11, 12]. Coefficients of
variation for these procedures were <5.0%. We used the four
variable (serum creatinine, age, sex and ethnicity) Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equa-
tion to calculate eGFR, which has been found to perform better
than the Modification of Diet in Renal Disease (MDRD) equa-
tion, with less bias and greater accuracy [16, 17].
Determinations of the following variables were performed as
previously described [11, 12, 18]: high-sensitivity C-reactive
protein (CRP), serum vitamin B12, total cholesterol, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, glucose and standard ApoE genotyping.
Medical records indicating a diagnosis of anemia were required
for identification of anemic participants. Hemoglobin levels and
complete blood count were not utilized in the present study, as
we did not anticipate an examination of kidney function as a
CVD-RF at the time of data collection.
Mean systolic BP (SBP) and diastolic BP (DBP) were based
on 15 BP measurements (five sitting, five standing and five
reclining). Hypertension was defined as SBP140 mmHg and/
or DBP 90 mmHg. Additional covariates that were used or
considered in various analyses included ethnicity (black versus
other), diabetes mellitus (DM), body mass index (BMI; kg/m2),
self-reported number of cigarettes smoked per week, self-
reported ounces of alcohol consumed per week, triglyceride lev-
els, the presence of CVD (self-reported and confirmed by medi-
cal records) and stroke. DM was defined by a fasting blood
glucose level of 126 mg/dL, treatment with insulin or oral
anti-diabetic agents. CVD was defined as the presence of: myo-
cardial infarction (4.3%), coronary artery disease (8.1%), heart
failure (2.5%), angina pectoris (6.0%) and/or transient ischemic
attack (3.7%) [19, 20]. Stroke (based on self-report or medical
records and confirmed by record review) was defined as a focal
neurological deficit of acute onset persisting for>24 h.
The protocol for this investigation was approved by the
University of Maine Institutional Review Board. We adhered to
the Declaration of Helsinki and obtained informed consent for
data collection from all study participants.
Neurocognitive tests
The cognitive outcomes utilized were raw scores from 22
neurocognitive tests, each of which is described in Table 1. In
previous MSLS studies, several of these measures have been
combined to produce four composite scores that each describe a
domain of cognitive functioning [9]. These domains are verbal
episodic memory, visual-spatial organization/memory
(VSOM), scanning and tracking, and working memory. Verbal
300 R.V. Torres et al.
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episodic memory is required for learning and remembering oral
and written material. Problem solving with respect to visual-
spatial relationships requires the use of VSOM. Scanning and
tracking requires attention and concentration, placing demands
on organization and planning. Working memory requires hold-
ing information in short-term memory while manipulating it to
perform a task. [21–25].
In order to examine a wider range of abilities in the present
study, neurocognitive tests assessing the following additional
domains were also included: executive function, abstract rea-
soning, language and general mental state. Executive function
describes the regulation of cognitive processes including: rea-
soning, task flexibility, problem solving, planning and execution
[26]. Abstract reasoning is utilized when analyzing information
and solving complex problems [9]. Language abilities are uti-
lized in the recall of simple object names. General mental state
relies on several functions incorporated in other domains,
including: attention and calculation, recall, orientation and lan-
guage [27].
Raw test scores for Trail Making Tests A and B were normal-
ized (log to the base 10) to achieve distributional assumptions.
The MMSE, CLOX 1 and CLOX 2 were also significantly
skewed, but could not be normalized with transformation and
were eliminated from analyses utilizing categorical regression
and v2. All other neurocognitive tests met assumptions for
normality.
Table 1. Neurocognitive tests used to assess the function of cognitive abilities and the domains that deﬁne them
Cognitive domains and the neurocognitive tests that define them Cognitive ability measured
Verbal episodic memory
Logical Memory: Immediate Recalla
Abbr. Logic Mem IR
Immediate verbal memory
Logical Memory: Delayed Recalla
Abbr. Logic Mem DR
Delayed verbal memory
Hopkins Verbal Learning Task
Abbr. Hopkins VLT
Verbal learning and memory
Visual-spatial organization/memory
Visual Reproduction: Immediate Recalla
Abbr. Vis Repro IR
Immediate recall, visual memory and visual-spatial problem solving
Visual Reproduction: Delayed Recalla
Abbr. Vis Repro DR
Delayed recall, visual memory and visual-spatial problem solving
Matrix Reasoningb Abstract reasoning and pattern recognition
Hooper Visual Organization Test
Abbr. Hooper VOT
Visual-spatial organization and demands on executive functioning
Object Assemblyc Speed of visual-spatial organization
Block Designc Visual-spatial perception, organization and construction
Scanning and tracking
Trail Making Ad Visual scanning and tracking; concentration and attention
Trail Making Bd Trail A plus demands on executive functioning
Digit Symbol Substitutionc
Abbr. Digit Symbol
Psychomotor performance
Symbol Searchb Visual processing speed
Working memory
Digit Span: Forwardc
Abbr. Digit Span F
Attention and concentration
Digit Span: Backwardc
Abbr. Digit Span B
Attention, concentration and working memory
Letter-Number Sequenceb
Abbr. Letter Number
Information processing while holding information in memory
Abstract reasoning
Similaritiesc Verbal intelligence and abstract reasoning
Executive functioning
CLOX 1e The ability to plan, organize and shift response set for the purpose of problem solving
CLOX 2e Copying skills
Controlled Oral Word Association Test
Abbr. COWA
Verbal ﬂuency and executive functioning
General mental state
Mini-Mental State Examination
Abbr. MMSE
Orientation, registration and attention
Language
Boston Naming Test
Abbr. Boston Naming
Ability to name objects; early loss seen in dementia
aOrigin: Wechsler Memory Scale-Revised.
bOrigin: Wechsler Adult Intelligence Scale III.
cOrigin: Wechsler Adult Intelligence Scale.
dOrigin: Halstead–Reitan Neuropsychological Test Battery.
eCLOX is the name of a clock drawing task.
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Statistical analyses
Mean (SD) cognitive scores were calculated for study partici-
pants with and without CKD, for each of the measures in our
neurocognitive test battery. The percentage of participants who
performed at least 1.0 SD and 1.5 SD below the mean were also
calculated and compared. In a normal distribution, 1 SD would
fall in the 16th percentile and 1.5 SD in the 7th percentile of
cognitive functioning.
Risk of modest and severe cognitive impairment on each of
the 22 neurocognitive tests was calculated using logistic regres-
sion [28]. Three sets of covariate controls, which were inde-
pendent predictors of new-onset CKD and cognitive
functioning identified in previous studies [9, 19, 29], were used
in each analysis. Models were introduced in a serial stepwise
order:
(i) Unadjusted model: CKD only;
(ii) Demographic-adjusted model: CKD þ age þ sex þ
education þ race;
(iii) Comorbidity-adjusted model: CKD þ age þ sex þ edu-
cation þ race þ DM þ SBP þ BMI þ cigarettes/week
þ HDL þ CVD þ stroke þ CRP.
To be included in these models, covariates had to be relevant to
the literature on CKD and cognitive function or significantly
related the predictor and outcome measures. All statistical anal-
yses were performed with IBM SPSS Statistics for Windows,
Version 22.0.
RESULTS
Participant characteristics
Table 2 displays the demographic and health characteristics
of study participants. Compared with the non-CKD reference
group, participants with CKD were significantly older, had
higher levels of CRP, higher SBP, consumed more ounces of
alcohol per week and had a higher prevalence of folate defi-
ciency, DM and CVD. Mean eGFR in the CKD group was 51.6
6 10.1 mL/min/1.73 m2 and 96% of these participants had
Stage 3 CKD.
CKD and cognitive performance
Mean (SD) cognitive scores for each measure are located in
Supplementary data, Appendix 2, Table 1a. This appendix also
contains proportions of persons with modest (Supplementary
data, Table 2a) and severe (Supplementary data, Table 3a) cog-
nitive impairment on each measure. Participants in the CKD
group had significantly higher percentages of impairment than
the reference group on at least one neurocognitive test in each
of the eight domains of functioning examined (all P< 0.05).
Tables 3 and 4 present the odds ratios (ORs) associated with
CKD for modest and severe cognitive impairment, respectively.
In the unadjusted model, participants with CKD were signifi-
cantly more likely to have modest impairment on all tests, with
the exception of Logical Memory Delayed Recall, Digit Span
Tests Forward and Backward and CLOX 1. The number of
Table 2. Demographic and health characteristics of study participants
Variable No CKD: eGFR 60 mL/min/
1.73 m2 (n ¼ 752)
CKD: eGFR <60 mL/min/
1.73 m2 (n ¼ 146)
P-value
Mean SD Mean SD
Age (years) 61.6 11.3 70.8 11.1 <0.001
Education (years) 14.6 2.7 14.2 2.7 0.082
CRP (mg/L) 3.9 4.2 5.2 5.8 0.002
Total cholesterol (mg/dL) 202.1 40.4 198.7 44.3 0.368
HDL cholesterol (mg/dL) 53.7 15.6 52.0 14.5 0.217
LDL cholesterol (mg/dL) 120.9 33.6 117.0 34.8 0.208
S BP (mmHg) 130.7 21.2 136.9 22.6 0.001
D BP (mmHg) 70.9 9.9 69.9 10.4 0.306
Cigarettes per week 8.8 34.4 7.0 28.7 0.551
BMI (kg/m2) 29.4 5.9 29.6 6.4 0.760
Alcoholic (oz/week) 1.6 3.1 1.0 1.9 0.027
Creatinine (mg/dL) 0.9 0.2 1.3 0.5 <0.001
CKD-EPI eGFR (mL/min/1.73 m2) 82.5 14.6 51.6 10.1 <0.001
Percentage Percentage
Women 58.0 62.0 0.394
Black 7.0 8.0 0.493
DM 12.0 25.0 <0.001
ApoE-e4 27.0 28.0 0.666
Folate deﬁciencya 0.0 1.0 0.018
B12 deﬁciency
b 5.0 5.0 0.831
Depressed moodc 10.0 11.0 0.760
Stroke 2.0 4.0 0.196
Cardiovascular diseased 12.0 25.0 <0.001
aDeﬁned as deﬁcient if folate <3 ng/mL.
bDeﬁned as deﬁcient if B12 <200 pg/mL.
cDeﬁned as having depressed mood if CES-D >16.
dDeﬁned as present if there was self-reported history of coronary artery disease, congestive heart failure, myocardial infarction, transient ischemic attack or angina pectoris.
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significant associations was attenuated with use of the demo-
graphic- and comorbidity-adjusted models. With use of the lat-
ter, the CKD group remained at significantly higher risk of
modest impairment on the Block Design and Object Assembly
tests, measures of VSOM, and the Trail Making Test B, a meas-
ure of scanning and tracking (all P < 0.05). In sensitivity analy-
ses utilizing the comorbidity-adjusted model without CRP,
modest impairment on the COWA and Hooper VOT were also
observed for the CKD group (both P < 0.05). The interaction
between the CRP and CKD groups did not significantly predict
modest impairment on any neurocognitive test when added to
the demographic-adjusted model.
In unadjusted models of severe cognitive impairment
(at least 1.5 SD below mean performance), participants with
CKD were more likely to have impaired performance than the
non-CKD reference group on nearly all measures, with the
exception of: Logical Memory Immediate and Delayed Recall,
Digit Span Forward and Backward and CLOX 1. With use of
the comorbidity-adjusted model, only the Boston Naming a
measure of language abilities, retained a significant OR (P <
0.01).
Figures 1 and 2 provide a graphic summary of the results for
the comorbidity-adjusted model and both impairment criteria
(1.0 SD and 1.5 SD, respectively) using forest plots.
Additional analyses
Supplementary data, Appendix 2, Table 4a shows results of
simple linear regression analyses (i.e. correlations presented in
regression metric) where continuously distributed eGFR (trun-
cated with scores 60 ¼ 60) was related to the continuous dis-
tribution of cognitive scores. The pattern of results for the
various models was similar to those reported for the logistic
regression analyses in Tables 3 and 4.
DISCUSSION
Previous studies provided strong support for an association
between early-stage CKD and lower cognitive function for one
or a few measures of cognitive ability or composite scores
reflecting broad domains of cognitive performance [1, 2, 5, 9].
Here, we are concerned with levels of lower cognitive perform-
ance recognized by psychologists as diagnostically meaningful
in studies of disease and aging [2, 4, 24].We report relationships
between CKD and cognitive ability for what may be the largest
battery of tests employed in studies of cardiovascular risk fac-
tors and cognitive performance [30].
We calculated the risk of impaired performance using two
criteria for impairment, 1.0 SD (modest) and 1.5 SD (severe)
below the mean for each measure. We used cross-sectional data
because one of our goals was to provide data that would allow
early-stage CKD to be used as a reference group in cross-
sectional studies of patients with ESRD, including studies of
longitudinal changes in cognitive performance. The participants
in our study represent a community-based, non-clinic sample
with early-stage CKD.
Table 3. ORs and 95% conﬁdence intervals (CIs) associated with modest cognitive impairment (1.0 SD below the mean) for persons in the CKD group
(eGFR <60 mL/min/1.73 m2)
Cognitive domain Neurocognitive test Zero order Demographic-adj.a Comorbidity-adj.b
OR 95% CI OR 95% CI OR 95% CI
Verbal episodic memory Logic Mem IR 1.73* [1.10–2.72] 1.14 [0.70–1.85] 1.14 [0.69–1.88]
Logic Mem DR 1.56 [1.00–2.45] 1.01 [0.63–1.63] 1.01 [0.61–1.66]
Hopkins VLT 2.74*** [1.84–4.10] 1.66* [1.07–2.59] 1.48 [0.92–2.36]
Visual-spatial organization/memory Vis Repro IR 2.87*** [1.91–4.32] 1.67* [1.06–2.62] 1.41 [0.87–2.29]
Vis Repro DR 2.80*** [1.87–4.19] 1.43 [0.92–2.24] 1.23 [0.77–1.98]
Matrix Reasoning 2.40*** [1.63–3.55] 1.40 [0.90–2.20] 1.13 [0.70–1.82]
Block Design 3.51*** [2.37–5.21] 2.42*** [1.55–3.78] 2.16** [1.35–3.48]
Object Assembly 2.86*** [1.92–4.24] 2.03*** [1.32–3.11] 1.82* [1.15–2.87]
Hooper VOT 3.20*** [2.07–4.94] 1.72* [1.06–2.79] 1.59 [0.96–2.65]
Scanning and tracking Trail Making Ac 2.43*** [1.61–3.69] 1.27 [0.80–2.02] 1.06 [0.65–1.74]
Trail Making Bc 3.23*** [2.12–4.92] 1.88** [1.17–3.02] 1.68* [1.02–2.78]
Digit Symbol 2.66*** [1.76–4.04] 1.45 [0.90–2.34] 1.15 [0.69–1.93]
Symbol Search 3.05*** [2.02–4.59] 1.65* [1.04–2.62] 1.36 [0.83–2.23]
Working memory Digit Span F 1.61 [0.98–2.63] 1.61 [0.95–2.73] 1.46 [0.84–2.56]
Digit Span B 1.40 [0.88–2.23] 1.35 [0.81–2.25] 1.24 [0.72–2.13]
Letter Number 2.10*** [1.34–3.27] 1.23 [0.75–2.00] 0.98 [0.58–1.65]
Abstract reasoning Similarities 2.23*** [1.48–3.37] 1.74* [1.07–2.82] 1.66 [1.00–2.75]
Executive functioning COWA 2.49*** [1.63–3.79] 1.85** [1.18–2.91] 1.58 [0.98–2.54]
CLOX 1 1.52 [0.90–2.59] 0.95 [0.54–1.69] 0.88 [0.48–1.63]
CLOX 2 1.57* [1.03–2.39] 1.07 [0.68–1.67] 1.02 [0.64–1.64]
General mental state MMSE 1.64* [1.01–2.67] 1.12 [0.64–1.93] 1.05 [0.59–1.87]
Language Boston Naming 1.97** [1.23–3.15] 1.63 [0.95–2.79] 1.49 [0.85–2.63]
aDemographic-adjusted model: age, sex, education and race.
bComorbidity-adjusted model: age, sex, education, race, diabetes, SBP, BMI, cigarettes/week, HDL, CVD, stroke and CRP.
cLog (base 10).
*P < 0.05.
**P < 0.01.
***P < 0.001.
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Using the modest and severe impairment criteria and the
unadjusted model, the risk for cognitive impairment was signifi-
cantly higher for persons with CKD for 18 out of 22 and 17 out
of 22 cognitive tests, respectively. With use of the comorbidity-
adjusted model, significant differences in risk between partici-
pants with and without CKD were attenuated for all but three
neurocognitive tests using the modest impairment criteria and
for all but one using the severe impairment criteria.
While direct effects of kidney disease on cognition have been
suggested [1, 2, 5, 9], some of the variables we include in the
comorbidity-adjusted model could mediate the relationship
between CKD and cognitive performance [29]. Persons with
CKD have a higher burden of traditional and non-traditional
CVD-RFs than those without, which may expose them to sys-
temic and cerebrovascular changes that increase the risk for
cognitive impairment [29, 31, 32].
Cerebrovascular disease is common at all stages of CKD and
has been associated with greater burden of white matter hyper-
intensities, atrophy and cerebral infarcts in the brain [29, 32].
Neurocognitive manifestations of cerebrovascular disease affect
executive functioning [32]. In the present study, CKD was asso-
ciated with greater odds of modest and severe cognitive impair-
ment on two tests indexing executive functioning in the zero-
order model. These results were attenuated with adjustment for
CVD-RFs. While this is of theoretical interest, the main purpose
of our study was to present data useful to nephrologists wishing
to evaluate cognitive deficit in their own patients. Kidney dis-
ease patients go to their physicians with many of the risk factors
we include in the comorbidity-adjusted model. Thus, we argue
that the most clinically relevant data in terms of test selection
Table 4. ORs and 95% CIs associated with severe cognitive impairment (1.5 SD below the mean) for persons in the CKD group (eGFR <60 mL/min/
1.73 m2)
Cognitive domain Neurocognitive test Zero order Demographic-adj.a Comorbidity-adj.b
OR 95% CI OR 95% CI OR 95% CI
Verbal episodic memory Logic Mem IR 1.47 [0.77–2.79] 0.83 [0.42–1.64] 0.78 [0.38–1.57]
Logic Mem DR 1.40 [0.77–2.54] 0.78 [0.41–1.48] 0.80 [0.41–1.54]
Hopkins VLT 1.97* [1.12–3.49] 0.97 [0.52–1.81] 0.73 [0.38–1.41]
Visual-spatial organization/memory Vis Repro IR 3.26*** [1.98–5.38] 1.64 [0.94–2.85] 1.25 [0.69–2.25]
Vis Repro DR 2.48*** [1.52–4.06] 1.20 [0.70–2.06] 0.95 [0.53–1.71]
Matrix Reasoning 2.05** [1.25–3.36] 1.08 [0.61–1.91] 0.75 [0.40–1.42]
Block Design 3.03*** [1.80–5.10] 2.04* [1.14–3.65] 1.54 [0.80–2.93]
Object Assembly 2.77*** [1.68–4.55] 1.73* [1.01–2.97] 1.62 [0.92–2.86]
Hooper VOT 3.41*** [1.99–5.85] 1.71 [0.95–3.10] 1.58 [0.84–2.96]
Scanning and tracking Trail Making Ac 2.48** [1.36–4.52] 1.22 [0.63–2.36] 1.02 [0.50–2.07]
Trail Making Bc 2.90*** [1.73–4.87] 1.61 [0.91–2.84] 1.35 [0.74–2.47]
Digit Symbol 2.70*** [1.55–4.70] 1.44 [0.78–2.67] 1.04 [0.53–2.04]
Symbol Search 2.70*** [1.47–4.96] 1.38 [0.71–2.67] 1.09 [0.54–2.20]
Working memory Digit Span F 1.61 [0.98–2.63] 1.61 [0.95–2.73] 1.46 [0.84–2.56]
Digit Span B 0.64 [0.15–2.81] 0.55 [0.12–2.57] 0.43 [0.08–2.18]
Letter Number 2.29** [1.35–3.90] 1.40 [0.78–2.52] 1.27 [0.69–2.35]
Abstract reasoning Similarities 1.93* [1.11–3.37] 1.45 [0.77–2.73] 1.28 [0.66–2.48]
Executive functioning COWA 3.07*** [1.70–5.53] 2.18* [1.15–4.11] 1.77 [0.91–3.47]
CLOX 1 1.19 [0.54–2.62] 0.65 [0.28–1.49] 0.60 [0.25–1.44]
CLOX 2 2.06* [1.06–4.02] 1.12 [0.55–2.28] 1.01 [0.47–2.15]
General mental state MMSE 2.26** [1.27–4.04] 1.57 [0.82–3.01] 1.44 [0.73–2.85]
Language Boston Naming 2.91*** [1.67–5.10] 2.40** [1.27–4.54] 2.65** [1.35–5.19]
aDemographic-adjusted model: age, sex, education and race.
bComorbidity-adjusted model: age, sex, education, race, diabetes, SBP, BMI, cigarettes per week, HDL, CVD, stroke and CRP.
cLog (base 10).
*P < 0.05.
**P < 0.01.
***P < 0.001.
FIGURE 1: Comorbidity-adjusted model odds ratios (OR) and 95 per-
cent conﬁdence intervals (CI) associated with modest impairment (1.0
SD below the mean) on each test for participants in the CKD group.
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and evaluation from among the 22 neurocognitive tests
employed in this study should be taken from the analyses utiliz-
ing the demographic-adjusted model.
The level of risk for modest impairment associated with
CKD ranged from 1.65 (for performance on the Symbol Search
test) to 2.42 (Block Design test) when the demographic-
adjusted model was employed. With control of the
comorbidity-adjusted model, risk for impairment on the Block
Design test, Object Assembly and Trail Making B were the only
remaining statistically significant tests. These tests index VSOM
and scanning and tracking, functions essential for problem solv-
ing and the ability to shift set, and should be tests of significant
interest to clinicians in terms of the ability of patients to be flexi-
ble and to adjust to changing demands of treatment.
CKD-associated risk for severe cognitive impairment was
observed for Block Design (OR ¼ 2.04), Object Assembly (OR
¼ 1.73) and COWA (OR¼ 2.18), measures of VSOM and exec-
utive functioning, when the demographically adjusted model
was employed. Risk for impairment was also observed in the
Boston Naming Test, a measure of language ability (OR ¼
2.40). Poor naming performance on this test is a good predictor
of subsequent dementia and is included in the Framingham
Heart Study Dementia Battery for this reason [33]. Risk
remained significant for the Boston Naming Test (OR ¼ 2.65)
with use of the comorbidity-adjusted model.
Limitations
The absence of hemoglobin determinations due to our
inability to anticipate an examination of kidney function and
cognition at the time of data collection was a limitation of our
study. We used eGFR data obtained on only one occasion to
define CKD. However, our eGFR criterion was consistent with
previous community-based studies and clinical trials that
defined CKD in this manner [6, 34, 35]. We also lacked data on
albuminuria, which has been suggested as a risk factor of
cognitive impairment and decline independent of renal filtra-
tion function [36]. Finally, although our goal in this study was
to examine cross-sectional data for early-stage CKD in order to
evaluate this group as a potentially useful control group for
studies of ESRD patients, it must be acknowledged that these
cross-sectional data do not permit us to determine causality in
the relationship between CKD and cognitive function.
Strengths
Our community-based study permitted us to examine rela-
tionships between CKD and cognition in a non-clinical sample,
unselected for kidney disease status, with blinded testing proce-
dures. Data on multiple risk factors for CKD and cognitive
impairment were present for use in statistical models, allowing
us to take into account variables deemed important by the liter-
ature. Finally, an extensive neurocognitive test battery was
employed. This has allowed us to provide nephrologists and
researchers with specific data on the abilities that are at the
highest risk for impairment with respect to early-stage CKD.
Perspectives
While we continue to argue that early-stage CKD patients
are ideal candidates for a reference group in studies of ESRD
[8], it is clear that even non-dialysis-dependent CKD is associ-
ated with deficit in some of the most important cognitive abil-
ities related to patient–physician communication. The extensive
data presented in this study will also allow investigators who
must use only one or a few tests due to time restrictions to select
those tests revealing the greatest vulnerability to CKD for use
with their own patients.
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